Related Experiment Video

Updated: Apr 3, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K

Relationship between stent type and quality of life after percutaneous coronary intervention for acute myocardial

Adnan K Chhatriwalla1, Lakshmi Venkitachalam2, Kevin F Kennedy3

  • 1Saint Luke's Mid America Heart Institute, Kansas City, MO; University of Missouri-Kansas City, Kansas City, MO.

American Heart Journal
|September 21, 2015
PubMed

Insights

Drug-eluting stents (DES) offer temporary health benefits after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). These benefits in quality of life and function were not sustained at 12 months post-procedure.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Health Outcomes Research

Background:

  • Drug-eluting stents (DES) are known to reduce restenosis compared to bare-metal stents (BMS).
  • The impact of stent type on patient health status following percutaneous coronary intervention (PCI) remains unclear.
  • This study investigates the association between DES versus BMS and health status outcomes in patients with acute myocardial infarction (AMI).

Purpose of the Study:

  • To determine if drug-eluting stent (DES) use is associated with improved health status outcomes compared to bare-metal stent (BMS) use in patients undergoing PCI.
  • To evaluate health status at 6 and 12 months post-PCI in patients treated with DES or BMS.
  • To assess the long-term impact of stent type on patient well-being after acute myocardial infarction (AMI).

Main Methods:

  • Analysis of 2,694 patients with AMI from the TRIUMPH and PREMIER registries who underwent PCI.
  • Comparison of health status at 6 and 12 months using Seattle Angina Questionnaire, SF-12, and PHQ-9.
  • Propensity score matching created comparable cohorts of 784 patients treated with DES and 784 with BMS.

Main Results:

  • Both DES and BMS groups showed significant health status improvements at 6 and 12 months post-PCI.
  • DES use was linked to a small, statistically significant improvement in quality of life and functional limitation scores at 6 months (p < .01).
  • These health status benefits associated with DES were not sustained at the 12-month follow-up (p > .10).

Conclusions:

  • In patients with AMI undergoing PCI, drug-eluting stent (DES) use demonstrated transient health status benefits.
  • The observed improvements in quality of life and function with DES were not sustained beyond 6 months.
  • This suggests that while DES may offer short-term advantages, long-term health status differences compared to BMS are minimal in this population.
Abstract

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.7K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
468
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.7K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
418
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
451
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
751
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
425